心肌梗死多支血管PCI完全血运重建的时机
该国际、开放标签、随机、非劣效性试验在欧洲37个中心纳入血流动力学稳定的STEMI合并多支冠状动脉病变患者,随机分为立即多支血管PCI组(418例)或罪犯病变PCI后19至45天分期多支血管PCI组(422例)。主要终点为随机化后1年全因死亡、非致死性心肌梗死、卒中、非计划缺血驱动血运重建或心力衰竭住院的复合终点。立即组主要终点事件发生率8.5%(35例),分期组16.3%(68例)(风险比0.52;95%CI 0.38~0.72;非劣效性P<0.001,优效性P<0.001)。结论认为立即多支血管PCI在主要终点风险上不劣于分期多支血管PCI。
要点
- 血流动力学稳定的STEMI合并多支冠状动脉病变患者,立即多支血管PCI组1年主要终点事件8.5%(35例)vs 分期组16.3%(68例),风险比0.52(95%CI 0.38~0.72),非劣效性P<0.001且优效性P<0.001。
- 非致死性心肌梗死:立即组2.0%(8例)vs 分期组5.3%(22例);非计划缺血驱动血运重建:立即组4.1%(17例)vs 分期组9.3%(39例)。
- 全因死亡、卒中、心力衰竭住院风险两组似乎相似。
- 严重不良事件:立即组104例 vs 分期组145例。
- 分期多支血管PCI安排在指数操作后19至45天。
适用人群与场景
- 血流动力学稳定的STEMI合并多支冠状动脉病变患者,在欧洲37个中心纳入。
处置流程与药物剂量
- 立即组:随机后立即行多支血管PCI。
- 分期组:先行罪犯病变PCI,随后在指数操作后19至45天行分期多支血管PCI处理非罪犯病变。
研究设计与关键结果
- 国际、开放标签、随机、非劣效性试验,在欧洲37个中心纳入血流动力学稳定的STEMI合并多支冠状动脉病变患者,立即多支血管PCI组418例,分期多支血管PCI组422例。
- 主要终点(随机化后1年全因死亡、非致死性心肌梗死、卒中、非计划缺血驱动血运重建或心力衰竭住院的复合终点):立即组8.5%(35例)vs 分期组16.3%(68例),风险比0.52(95%CI 0.38~0.72),非劣效性P<0.001,优效性P<0.001。
- 非致死性心肌梗死:立即组2.0%(8例)vs 分期组5.3%(22例)。
- 非计划缺血驱动血运重建:立即组4.1%(17例)vs 分期组9.3%(39例)。
- 全因死亡、卒中、心力衰竭住院风险两组似乎相似。
- 严重不良事件:立即组104例 vs 分期组145例。
证据类型、等级与局限
- 证据类型:国际、开放标签、随机、非劣效性试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于血流动力学稳定的STEMI合并多支冠状动脉病变患者,立即多支血管PCI在1年主要复合终点风险上不劣于分期多支血管PCI(风险比0.52;95%CI 0.38~0.72;非劣效性P<0.001),且优效性检验P<0.001。
指南或共识出处
- MULTISTARS AMI试验(ClinicalTrials.gov注册号NCT03135275),由Boston Scientific资助。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: In patients with ST-segment elevation myocardial infarction (STEMI) with multivessel coronary artery disease, the time at which complete revascularization of nonculprit lesions should be performed remains unknown.
METHODS: We performed an international, open-label, randomized, noninferiority trial at 37 sites in Europe. Patients in a hemodynamically stable condition who had STEMI and multivessel coronary artery disease were randomly assigned to undergo immediate multivessel percutaneous coronary intervention (PCI; immediate group) or PCI of the culprit lesion followed by staged multivessel PCI of nonculprit lesions within 19 to 45 days after the index procedure (staged group). The primary end point was a composite of death from any cause, nonfatal myocardial infarction, stroke, unplanned ischemia-driven revascularization, or hospitalization for heart failure at 1 year after randomization. The percentages of patients with a primary or secondary end-point event are provided as Kaplan-Meier estimates at 6 months and at 1 year.
RESULTS: We assigned 418 patients to undergo immediate multivessel PCI and 422 to undergo staged multivessel PCI. A primary end-point event occurred in 35 patients (8.5%) in the immediate group as compared with 68 patients (16.3%) in the staged group (risk ratio, 0.52; 95% confidence interval, 0.38 to 0.72; P<0.001 for noninferiority and P<0.001 for superiority). Nonfatal myocardial infarction and unplanned ischemia-driven revascularization occurred in 8 patients (2.0%) and 17 patients (4.1%), respectively, in the immediate group and in 22 patients (5.3%) and 39 patients (9.3%), respectively, in the staged group. The risk of death from any cause, the risk of stroke, and the risk of hospitalization for heart failure appeared to be similar in the two groups. A total of 104 patients in the immediate group and 145 patients in the staged group had a serious adverse event.
CONCLUSIONS: Among patients in hemodynamically stable condition with STEMI and multivessel coronary artery disease, immediate multivessel PCI was noninferior to staged multivessel PCI with respect to the risk of death from any cause, nonfatal myocardial infarction, stroke, unplanned ischemia-driven revascularization, or hospitalization for heart failure at 1 year. (Supported by Boston Scientific; MULTISTARS AMI ClinicalTrials.gov number, NCT03135275.).
参考来源
- Stähli BE, Varbella F, Linke A, et al. Timing of Complete Revascularization with Multivessel PCI for Myocardial Infarction. N Engl J Med. 2023. PMID: 37634190. doi:10.1056/NEJMoa2307823
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。